Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 311

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Circulating Levels of Sclerostin Are Increased in Patients with Type 2 Diabetes Mellitus

García-Martín, Antonia, Rozas-Moreno, Pedro, Reyes-García, Rebeca, Morales-Santana, Sonia, García-Fontana, Beatriz, García-Salcedo, José A., Muñoz-Torres, Manuel·2012·The Journal of Clinical Endocrinology & Metabolism

Abstract

CONTEXT: Diabetes mellitus is a risk factor for osteoporotic fractures. Sclerostin is an inhibitor of bone formation. However, there are no data about sclerostin levels in type 2 diabetes mellitus (T2DM). OBJECTIVES: The aims were to evaluate serum sclerostin in T2DM patients and to analyze its relationship with bone metabolism. DESIGN, SETTING, AND PATIENTS: This was a cross-sectional study. We compared serum sclerostin in the T2DM group (n = 74) and control group (n = 50), and we analyzed its relationship with calciotropic hormones, bone turnover markers, bone mineral density (BMD), and morphometric vertebral fractures. RESULTS: Sclerostin levels were significantly higher in T2DM patients than control subjects (P < 0.001) and in T2DM males than in T2DM females (P < 0.001). Serum sclerostin was positively correlated with age in males T2DM (P = 0.031). In linear regression analysis, gender, study group, and age were predictive of sclerostin levels (P < 0.05). Sclerostin concentrations were positively associated with duration of T2DM (P = 0.064) and glycated hemoglobin (P = 0.074) independently of age in T2DM patients. Sclerostin was inversely related to bone turnover markers (P < 0.05) and positively related to lumbar spine, femoral neck, and total hip BMD (P < 0.05) in the T2DM group. Sclerostin was significantly lower in osteoporotic than nonosteoporotic patients with T2DM (P = 0.048). CONCLUSIONS: Circulating sclerostin is increased in T2DM independently of gender and age. Serum sclerostin is also correlated with duration of T2DM, glycated hemoglobin, bone turnover markers, and BMD in T2DM patients. Additional studies are needed to evaluate the role of sclerostin on bone metabolism in this population.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2011-2186

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

See all 311

Metadata

Authors
García-Martín, A., Rozas-Moreno, P., Reyes-García, R., Morales-Santana, S., García-Fontana, B., García-Salcedo, J. A., & Muñoz-Torres, M.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2012-01
Volume
97
Issue
1
Pages
234-241
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2041638197
Cited by
311
References
38
FWCI
21.10
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Circulating Levels of Sclerostin Are Increased in Patients with Type 2 Diabetes Mellitus. https://app.cochat.ai/papers/10.1210/jc.2011-2186
The paper
García-Martín, A., Rozas-Moreno, P., Reyes-García, R., Morales-Santana, S., García-Fontana, B., García-Salcedo, J. A., & Muñoz-Torres, M. (2012). Circulating Levels of Sclerostin Are Increased in Patients with Type 2 Diabetes Mellitus. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2011-2186

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.